BHARAT BIOTECH

In News

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development - GSK

GSK - Jun 12, 2025

GSK, Bharat Biotech to slash the price of first malaria vaccine to less than $5 per dose by 2028 - Fierce Pharma

Fierce Pharma - Jun 25, 2025

Bharat Biotech acquires licence to develop GSK's Shigella vaccine - Pharmaceutical Technology

Pharmaceutical Technology - Jun 13, 2025

GSK offloads shigella vaccine to Bharat ahead of phase 3, vows to support fundraising - Fierce Biotech

Fierce Biotech - Jun 12, 2025

Bharat Biotech opens $75m CGT facility in India - BioProcess International

BioProcess International - Mar 31, 2025

GSK Licenses altSonflex1-2-3 Shigella Vaccine to Bharat Biotech - Pharmaceutical Executive

Pharmaceutical Executive - Jun 12, 2025

Bharat Biotech sets up CRDMO arm to focus on cell and gene therapies - The Hindu

The Hindu - Nov 03, 2025

Bharat Biotech forays into CRDMO space with new cell & gene therapies arm Nucelion Therapeutics - Times of India

Times of India - Nov 03, 2025

GSK Licenses Shigella Vaccine to Bharat Biotech - Yahoo Finance

Yahoo Finance - Jun 16, 2025

Bharat Biotech launches Next-Gen Cell and Gene Therapy CRDMO Nucelion - BioSpectrum India

BioSpectrum India - Nov 03, 2025

Bharat Biotech Establishes Nucelion Therapeutics in Hyderabad to Focus on Cell and Gene Therapy - geneonline.com

geneonline.com - Nov 03, 2025

Bharat Biotech, GSK to halve price of malaria vaccine by 2028 - The Economic Times

The Economic Times - Jun 25, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment